Department of Neuropsychiatry, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):300-6. doi: 10.1016/j.pnpbp.2011.11.008. Epub 2011 Nov 21.
The high use of long-term benzodiazepines (BZDs) with second-generation antipsychotics (SGAs) has been identified as an important issue in the treatment of schizophrenia in Japan. The aim of this study was to evaluate the effects of gradual reduction or discontinuation of daytime BZD use on cognitive function and quality of life (QOL) in patients with chronic schizophrenia receiving an SGA.
Thirty schizophrenic patients who had received an SGA with concomitant BZDs for at least 3 months were enrolled. Before and 4 weeks after tapering of daytime BZDs, the Brief Assessment of Cognition in Schizophrenia Japanese-language version (BACS-J) and the Schizophrenia Quality of Life Scale Japanese-language version (SQLS-J) were administered. Clinical evaluation also included the Positive and Negative Syndrome Scale (PANSS). To compare for practice effects on the BACS-J, 10 patients with chronic schizophrenia were assessed without tapering BZDs.
BZDs were reduced or discontinued safely in most patients, and no emergent withdrawal symptoms were observed. Significant improvements were shown in verbal memory, working memory, and composite score, as measured by the BACS-J without practice effects. In addition, the motivation/energy score on the SQLS-J, the negative symptoms and total scores on the PANSS significantly improved after tapering BZDs.
Reduction or discontinuation of long-term daytime use of BZDs may be warranted in patients with schizophrenia treated with SGAs, as it may improve cognitive function, subjective QOL, and psychiatric symptoms with no significant adverse effects.
在日本,精神分裂症的治疗中,第二代抗精神病药物(SGAs)联合长期苯二氮䓬类药物(BZDs)的高使用率已被确定为一个重要问题。本研究旨在评估慢性精神分裂症患者在接受 SGA 治疗时逐渐减少或停止日间 BZD 使用对认知功能和生活质量(QOL)的影响。
共纳入 30 名接受 SGA 联合 BZD 治疗至少 3 个月的精神分裂症患者。在减少日间 BZD 剂量之前和 4 周后,分别进行了日本版简明精神分裂症认知评估量表(BACS-J)和日本版精神分裂症生活质量量表(SQLS-J)的评估。临床评估还包括阳性和阴性症状量表(PANSS)。为了比较 BACS-J 的练习效应,对 10 名无 BZD 减量的慢性精神分裂症患者进行了评估。
大多数患者安全地减少或停止了 BZD 的使用,且未观察到急性戒断症状。BACS-J 测量的言语记忆、工作记忆和综合评分显著改善,且无练习效应。此外,SQLS-J 的动机/能量评分、PANSS 的阴性症状和总分在减少 BZD 剂量后均显著改善。
对于接受 SGA 治疗的精神分裂症患者,减少或停止长期日间使用 BZD 可能是合理的,因为它可能改善认知功能、主观 QOL 和精神症状,且无明显不良反应。